Savara (SVRA) Retained Earnings (2010 - 2026)
Savara's (SVRA) quarterly Retained Earnings came in at -$645.4 million in Q1 2026, down 25.1% year-on-year from -$861.7 million in Q1 2025, and down 6.14% on a QoQ basis from -$608.1 million in Q4 2025.
Savara (SVRA) Retained Earnings (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Retained Earnings data on file, last reported at -$645.4 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 25.1% year-over-year to -$645.4 million in Q1 2026; TTM through Mar 2026 was -$645.4 million, a 25.1% decrease from a year earlier, with the FY2025 full-year figure at -$608.1 million, down 24.29% from the prior year.
- Retained Earnings for Q1 2026 stood at -$645.4 million, down from -$608.1 million in the prior quarter.
- Over the last five years, Retained Earnings for SVRA reached as high as -$461000.0 in Q1 2023 and fell as low as -$645.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$354.5 million across 5 years, with a median of -$393.4 million in 2023.
- Across the five-year window, Retained Earnings slumped 115328.07% in 2022 and soared 99.85% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$605000.0 in 2022, then tumbled by 64919.67% to -$393.4 million in 2023, then retreated by 24.37% to -$489.2 million in 2024, then retreated by 24.29% to -$608.1 million in 2025, then dropped by 6.14% to -$645.4 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$645.4 million in Q1 2026, -$608.1 million in Q4 2025, and -$575.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | -645.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -645.40 Mn |
| Dec 31, 2025 | -608.09 Mn |
| Sep 30, 2025 | -575.90 Mn |
| Jun 30, 2025 | -546.29 Mn |
| Mar 31, 2025 | -515.90 Mn |
| Dec 31, 2024 | -489.25 Mn |
| Sep 30, 2024 | -460.21 Mn |
| Jun 30, 2024 | -880,000.00 |
| Mar 31, 2024 | -413.72 Mn |
| Dec 31, 2023 | -393.37 Mn |
| Sep 30, 2023 | -377.30 Mn |
| Jun 30, 2023 | -360.67 Mn |
| Mar 31, 2023 | -461,000.00 |
| Dec 31, 2022 | -605,000.00 |
| Sep 30, 2022 | -328.40 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Mar 31, 2022 | -308.82 Mn |
| Dec 31, 2021 | -300.52 Mn |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | -278.67 Mn |